Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study
GSK authors: Barbara J Klencke, MD; Jing Yu, PhD; Rafe Donahue, PhD; Jun Kawashima, MD
